Leaps by Bayer — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Celea Therapeuticsceleatx.cominJul 2026 · $180M
Celea develops deupirfenidone, a pulmonary therapeutic targeting idiopathic pulmonary fibrosis in partnership with physicians and patient advocacy organizations.
BiotechHealthtechMedical Devices
Co-investorsRA CapitalPureTech Health
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.